|Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer|
Authors: A. Morán, P. Iniesta, C. García-Aranda, C. De Juan, A. Díaz-López, A. Sánchez-Pernaute, A. J. Torres, E. Díaz-Rubio, J. L. Balibrea, M. Benito
Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense, 28040-Madrid, Spain
The main aim of this study was to evaluate the clinical relevance of Gelatinases in colorectal cancer (CRC). Ninety-five CRCs and their paired normal tissues were investigated to detect total levels of MMP-9, MMP-2, and the tissue inhibitors TIMP-1 and TIMP-2. Also, pro-MMP and MMP activity, and potential associations with clinical parameters were estimated. MMP-9, MMP-2 and TIMP-1 levels were greater in CRCs than in normal tissues, differences being significant for MMP-9 and TIMP-1. However, TIMP-2 showed significantly lower levels in tumour samples. Moreover, significant differences in the state of activation between gelatinases were found. TIMP-1 low levels were significantly associated with poor clinical outcome of patients. According to these data, different roles have to be attributed to MMP-2 and MMP-9 in CRC progression. Moreover, TIMP-1 level evaluation emerges as the main prognostic factor in relation to Gelatinases A and B activity in CRC.